Skip to main content

Novel Rx

      Lots of lupus research and the New ACR Guidelines on Lupus Nephritis management were presented today. These and other highlights as featured on our Twitter (X) feed from ACR24 in Washington, DC.…
      A#2582 McInnes
      Sonelokimab - IL17A,F nanobody
      Prior P2 in PsO, HS
      ARGO: P2 W24 RCT
      Significant improv in ACR response
      Hi
      1 month ago
      A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK
      A#2584 Mease
      Zasocitinib TAK-279 - potent, selective TYK2i
      P2b, 12w PsA RCT
      15/30 mg - similar response, better than PBO
      1 month ago
      A#2584 Mease Zasocitinib TAK-279 - potent, selective TYK2i P2b, 12w PsA RCT 15/30 mg - similar response, better than PBO for ACR20/50/70, MDA, DAPSA, PASDAS 29% MDA v 13% PBO Safety no signal for MACE, cancer, serious ifn, death. Mild acne signal noted @RheumNow #ACR24 https://t.co/1eqD9R5fLe
      Selective TYK2i zasocitinib, results of Phase 2 DBRCTDose dependent improvements in various PsA outcomes; NNT~5 for DA
      1 month ago

      Selective TYK2i zasocitinib, results of Phase 2 DBRCT Dose dependent improvements in various PsA outcomes; NNT~5 for DAS28 remission, NNT~20 for PASDAS Hard to compare to current agents, somewhere between JAKs (woot!) & "apremlist zone" đź«Ł #ACR24 @RheumNow Abstr#2584 #ACRbest https://t.co/t0y6C618ll

      Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. By enhancing insulin secretion, suppressing glucagon release, and slowing…
      Evaluation of Bimekizumab in PsA

      At last year’s ACR, I shared about the early clinical trial data on bimekizumab in
      1 month ago
      Evaluation of Bimekizumab in PsA At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv
      A#2363
      Deodhar
      Bimekizumab fast time to work:
      BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as
      1 month ago
      A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m
      ×